Prognosis
Alzheimer's Cure Search Leads to a Crash, Raises More Questions
- Biogen and Eisai used a novel method to analyze their trial
- About 200 experimental drugs for the disease have failed
This article is for subscribers only.
A promising drug trial excites doctors and investors. The company’s stock soars. Then more data pours in, confusion grows, the shares crash and the questions start -- will this Alzheimer’s drug fail like all the others?
That’s been the history of treatments for the neurodegenerative disease, which affects about 35 million people around the world. There’s no approved product that can slow or stop the ailment, and about 200 drugs have failed despite years and billions of dollars of effort.